Takeda Shareholders Approve Weber As COO Setting Up Leadership Handover
This article was originally published in PharmAsia News
Christophe Weber wins shareholder approval as chief operating officer at Takeda as expected, setting up a leadership change at Japan’s top, and oldest, drug company over the opposition of some family members.
You may also be interested in...
Jury awarded $1.5 million in compensatory damages and $9 billion in punitive damages against Takeda and Lilly; judge said jurors could consider Takeda’s destruction of evidence, which included a concern about Actos’ “margin of safety.”
Takeda CEO Calls For A Paradigm Shift In Japanese R&D; BIO Japan Conference Takeaway Message, Head West...To China
YOKOHAMA, Japan - Takeda Pharmaceutical Co. CEO Yasuchika Hasegawa encouraged his fellow Japanese companies to embrace a paradigm shift in their approach to R&D, which includes being open to reverse innovation and rethinking how global R&D can be localized
PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.